[Press Release] PCMO, Exceeds 84% in 2023 CDMO Service Satisfaction

  • ER
  • 2023.12.13

-  All 7 surveyed companies responded positively to the intention of reusing CDMO services

-  Some clients expressed their intention to utilize 'mRNA production lines' in the future.



 PCMO Aerial Photo


  PCMO (Director Min Cho) announced the results of the 2023 service satisfaction survey. The survey targeted seven client companies utilizing Contract Development and Manufacturing Organization (CDMO), quality testing, and storage services. The average satisfaction level was reported as '84%', indicating satisfaction or higher.

 

  The survey comprised a total of 9 categories and 33 items, collecting opinions from various perspectives. Among them, ▲ Request and Initial Discussion ▲ Contract Negotiation and Execution ▲ Raw Material and Product Inbound/Outbound ▲ CDMO Task Execution ▲ Project Issues (Incidents/Deviation/Major Changes) ▲ Vendor Audit ▲ Task Completion Procedures ▲ Responsiveness ▲ Schedule Management were included.

 

  Survey results showed that, regarding the Center's CDMO requests and initial discussions, 5 companies (71.4%) responded with 'Extremely Satisfied,' and 2 companies (28.6%) responded with 'Satisfied.' For the intention to reuse services in the future, 5 companies (71.4%) responded with ' Extremely agree,' and 1 company (14.3%) responded with 'Agree.'

 

  Specifically, for CDMO tasks, respondents expressed satisfaction with ▲ Directional proposals and consulting based on experience/expertise ▲ Enthusiasm for monthly meetings ▲ Thorough review of process data and immediate reporting of issues.

 

  Differences between the Center and other CDMO companies, as perceived by clients, included ▲ High GMP standards (cGMP level) ▲ Reasonable costs ▲ Experience in mRNA production ▲ Government-funded establishment. Additionally, clients requested services such as ▲ mRNA DS production and DP process optimization research (freeze-drying) ▲ mRNA characteristic analysis from the Center.

 

  Furthermore, PCMO has been executing a project for the establishment of a 'mRNA Vaccine Manufacturing Facility’ since 2022, with a total budget of 43 billion won from the Ministry of Trade, Industry and Energy and Jeollanam-do. The Center aims to complete the construction and operation of production lines by 2025.